Biohaven CEO says drug approval is ‘enormous’ for migraine sufferers


Get real time updates directly on you device, subscribe now.

Biohaven CEO Vlad Coric instructed CNBC Tuesday a up to date approval of the corporate’s migraine drug will “change the paradigm” of migraine prevention and remedy.

The U.S. Meals and Drug Management ultimate week authorized the medication, Nurtec ODT, for preventative remedy of migraines. That comes a few 12 months after Nurtec used to be first introduced to regard the indications of debilitating complications, making it the primary tablet authorized for each acute remedy and prevention, in line with Coric.

“This is a monumental approval for Biohaven and patients with migraine,” Coric stated in a “Mad Money” interview with Jim Cramer.

“I’ve been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,” Coric stated. “This is going to change the paradigm in which migraine is treated.”

The New Haven, Connecticut-based pharmaceutical corporate has recruited superstar names like actress Whoopi Goldberg and type Khloe Kardashian to advertise the remedy.

Biohaven stocks closed at $95.36 apiece Tuesday, up 6.5% from the place it ultimate traded earlier than the announcement.

Get real time updates directly on you device, subscribe now.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More